Moderna Stock Executives

MRNA -  USA Stock  

USD 132.06  5.56  4.04%

Moderna employes about 2.7 K people. The company is managed by 19 executives with total tenure of roughly 109 years, averaging almost 5.0 years of service per executive having 142.11 employees per reported executive. Analysis of Moderna management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Moderna future performance.
Additionally, see Stocks Correlation.
  
Refresh
  Robert Moscato  CEO
CEO
  Vuong Trieu  Chairman
Chairman of the Board, CFO, Treasurer
  Michael French  Chairman
Chairman, CEO and Pres

Moderna Return on Sales

0.77

Share

Moderna Management Team Effectiveness

Moderna has return on total asset (ROA) of 51.93 % which means that it generated profit of $51.93 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 146.08 %, meaning that it created $146.08 on every $100 dollars invested by stockholders. Moderna management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Average Assets is expected to grow to 0.71. The current year Return on Average Equity is expected to grow to 1.51. Moderna Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 24.67 Billion. The current year Current Assets is expected to grow to about 17.3 B, whereas Tax Assets are forecasted to decline to about 291.7 M.

Moderna Quarterly Total Assets

27.61 Billion

Share
As of May 24, 2022, Weighted Average Shares is expected to decline to about 339.6 M. In addition to that, Weighted Average Shares Diluted is expected to decline to about 357 M

Moderna Workforce Comparison

Moderna is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 3,009. Moderna totals roughly 2,700 in number of employees claiming about 90% of stocks in Biotechnology industry.

Moderna Profit Margins

The company has Profit Margin (PM) of 66.06 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 71.98 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.72.

Moderna Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moderna insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Moderna Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Moderna Price Series Summation is a cross summation of Moderna price series and its benchmark/peer.
.

Moderna Notable Stakeholders

A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Moscato - CEOProfile
Vuong Trieu - Chairman of the Board, CFO, TreasurerProfile
Michael French - Chairman, CEO and PresProfile
Uli Hacksell - Chairman of the BoardProfile
Daniel Geffken - Interim CFOProfile
Amit Shah - CFOProfile
Eric Teague - CFOProfile
Mihir Munsif - COOProfile
Nancy Phelan - DirectorProfile
Philip Ranker - DirectorProfile
Joseph Ramelli - Independent DirectorProfile
Tim Boris - DirectorProfile
Philippe Calais - DirectorProfile
Donald Williams - Independent DirectorProfile
Stefan Loren - Lead Independent DirectorProfile
Isaac Blech - DirectorProfile
Larn Hwang - Chief Scientific OfficerProfile
Erik Emerson - Chief Commercial OfficerProfile
Peter Weinstein - Chief Legal OfficerProfile

About Moderna Management Performance

The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets 0.66  0.71 
Return on Average Equity 1.40  1.51 
Return on Invested Capital 3.25  3.51 
Return on Sales 0.72  0.77 
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.
The data published in Moderna's official financial statements usually reflect Moderna's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moderna. For example, before you start analyzing numbers published by Moderna accountants, it's critical to develop an understanding of what Moderna's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moderna's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moderna. Please utilize our Beneish M Score to check the likelihood of Moderna's management to manipulate its earnings.

Moderna Workforce Analysis

Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.

Moderna Manpower Efficiency

Return on Moderna Manpower

Revenue Per Employee6.8 M
Revenue Per Executive972.1 M
Net Income Per Employee4.5 M
Net Income Per Executive642.1 M
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.